Large Investor Urges Celera to Renegotiate Sale to Quest | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Activist hedge fund business Starboard Value & Opportunity Fund today said it has delivered a letter to the CEO of Celera expressing concerns about the proposed sale of the company to Quest Diagnostics and asking Celera to renegotiate a better deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.